1. Home
  2. BL vs TSHA Comparison

BL vs TSHA Comparison

Compare BL & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackLine Inc.

BL

BlackLine Inc.

N/A

Current Price

$32.81

Market Cap

1.7B

Sector

Technology

ML Signal

N/A

TSHA

Taysha Gene Therapies Inc.

N/A

Current Price

$5.58

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BL
TSHA
Founded
2001
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
BL
TSHA
Price
$32.81
$5.58
Analyst Decision
Buy
Strong Buy
Analyst Count
13
8
Target Price
$56.62
$11.63
AVG Volume (30 Days)
971.7K
2.1M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.56
EPS
0.40
N/A
Revenue
$177,031,000.00
$9,773,000.00
Revenue This Year
$12.62
N/A
Revenue Next Year
$10.90
$1,152.42
P/E Ratio
$84.20
N/A
Revenue Growth
43.78
17.28
52 Week Low
$24.70
$2.72
52 Week High
$59.57
$7.30

Technical Indicators

Market Signals
Indicator
BL
TSHA
Relative Strength Index (RSI) 60.27 38.99
Support Level $27.74 $5.28
Resistance Level $34.09 $6.01
Average True Range (ATR) 1.34 0.28
MACD 0.14 -0.07
Stochastic Oscillator 81.42 0.50

Price Performance

Historical Comparison
BL
TSHA

About BL BlackLine Inc.

BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: